In Response to: 'Should We be Offering our Patients with Oligometastases Stereotactic Ablative Body Radiotherapy?' by Ostler et al. and 'Should We be Offering our Patients with Oligometastases Stereotactic Ablative Body Radiotherapy – No' by Macbeth and Hughes-Davies. Issue 4 (April 2022) - Phillips, I.; Olson, R.; Palma, D.; Harrow, S.